Image
The rescheduling of marijuana from a Schedule I to Schedule III drug in the United States would be transformative for the cannabis sector, CEOs of leading cannabis companies believe. Last week, the Department of Health and Human Services (HHS) made a recommendation to the Drug Enforcement